Looks back at real-world treatment of myeloma with daratumumab, lenalidomide and dexamethasone
Reviews past records of adults with myeloma, ineligible for transplant, given daratumumab, lenalidomide and dexamethasone.
Plain-language title generated from the registry record
Registry title: REal World MAIA UK OutcomEs
Key facts
- Where
- Wolverhampton, United KingdomSee the site
Where in United Kingdom
- The Royal Wolverhampton NHS TrustWolverhampton, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Royal Wolverhampton Hospitals NHS Trust
- Trial code
- NCT07532473
- Record updated
- 15 September 2026
- Original description
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.Read full original descriptionShow less
A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Inclusion: Age ≥18 years; Diagnosis of NDMM; Not eligible for autologous stem cell transplant at diagnosis; Received frontline DRd treatment following NICE approval (post-September 2023); Minimum 3 months of follow-up data available.
Exclusion: Participation in an interventional clinical trial for first-line therapy; DRd used in relapsed/refractory setting rather than newly diagnosed disease; Insufficient treatment or follow-up data for analysis.